References
- Traynor B. J., Codd M. B., Corr B., Forde C., Frost E., Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population‐based study. Neurology 1999; 52: 504–9
- Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two‐stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660–3
- Whitehead J. The Design and Analysis of Sequential Clinical Trials. J.Wiley and Sons Ltd., Chichester 1997, Rev. 2nd edn
- Whitehead J. Monotherapy trials: sequential design. Epilepsy Res 2001; 45: 81–7
- Graf M., Ecker D., Horowski R., Kramer B., Riederer P., Gerlach M., et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add‐on therapy to riluzole: results of a placebo‐controlled double‐blind study. J Neural Transm 2005; 112: 649–60
- Skovlund E., Walloe L. Sequential or fixed sample trial design? A case study by stochastic simulation. J Clin Epidemiol 1991; 44: 265–72
- Bolland K., Weeks A., Whitehead J., Lees KR; GAIN International Steering Committee and the Investigators. How a sequential design would have affected the GAIN International Study of gavestinel in stroke. Cerebrovasc Dis 2004; 17: 111–7
- Groeneveld G. J., van der Tweel I., Wokke J. H. J., Van den Berg L. H. Sequential designs for clinical trials in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 1–6